Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
101.62
+1.13 (1.12%)
Mar 4, 2026, 10:40 AM EST - Market open
Revolution Medicines Employees
Revolution Medicines had 883 employees as of December 31, 2025. The number of employees increased by 349 or 65.36% compared to the previous year.
Employees
883
Change (1Y)
349
Growth (1Y)
65.36%
Revenue / Employee
n/a
Profits / Employee
-$1,281,202
Market Cap
20.14B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 883 | 349 | 65.36% |
| Dec 31, 2024 | 534 | 156 | 41.27% |
| Dec 31, 2023 | 378 | 132 | 53.66% |
| Dec 31, 2022 | 246 | 58 | 30.85% |
| Dec 31, 2021 | 188 | 63 | 50.40% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| BioNTech SE | 6,772 |
| Moderna | 4,700 |
| Genmab | 2,973 |
| Incyte | 2,844 |
| Insmed | 1,664 |
| Ascendis Pharma | 1,189 |
| Ionis Pharmaceuticals | 1,069 |
| BridgeBio Pharma | 839 |
RVMD News
- 23 hours ago - Revolution Medicines, Inc. (RVMD) Presents at TD Cowen 46th Annual Health Care Conference Transcript - Seeking Alpha
- 6 days ago - Revolution Medicines, Inc. (RVMD) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 6 days ago - Revolution Medicines Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress - GlobeNewsWire
- 7 days ago - Revolution Medicines to Participate in TD Cowen 46th Annual Health Care Conference - GlobeNewsWire
- 13 days ago - Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2025 After Market Close on February 25, 2026 - GlobeNewsWire
- 21 days ago - Revolution Medicines, Inc. (RVMD) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript - Seeking Alpha
- 27 days ago - Revolution Medicines to Participate in Guggenheim Securities Emerging Outlook: Biotech Summit 2026 - GlobeNewsWire
- 4 weeks ago - Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance - Seeking Alpha